Natural infection with Neisseria gonorrhoeae may elicit a substantial antibody response directed against gonococcal lipooligosaccharide. Monoclonal antibody (MAb) 2C7 recognized a gonococcal lipooligosaccharide epitope, identified the epitope directly in 94% of 68 consecutive culture-positive genital secretions, and recognized 9S% of 101 randomly chosen fresh (second-passage) gonococcal isolates. The epitope was stably maintained after multiple in vitro passages and did not compete with any of the known cross-reactive human glycosphingolipid structures. MAb 2C7 mediated in vitro killing and phagocytosis by human polymorphonuclear leukocytes of 1 serum-sensitive (sialylated or not) and 1 stably serum-resistant gonococcal isolate that expressed the epitope. Gonococcal endometritis and disseminated infection elicited increases (6.S-fold IgM, 4.4-fold IgG; 18-fold IgM, 17-fold IgG, respectively) in anti-2C7 epitope antibody. Immunization with a gonococcal outer membrane vaccine elicited a mean 44.S-fold increase in IgG anti-2C7 epitope antibody in 20 of 28 subjects. The epitope identified by MAb 2C7 may represent an excellent target for a potentially protective gonococcal vaccine candidate.
Immunogenicity of Neisseria gonorrhoeae Lipooligosaccharide Epitope 2C7, Widely Expressed In Vivo with No Immunochemical Similarity to Human Glycosphingolipids
boside (Gal,BI-4GlcNAc,BI-3Gal,BI-4Glc-ceramide) [15, 16] and globotriose (Galal-4Gal,BI-4Glc-ceramide) [16] structures. These similarities may contribute to pathogenesis by allowing the gonococcus to mimic human mucosal cellular surfaces and thus evade detection by immune defenses. In the context of vaccine antigen development, the possibility that such similarity would evoke an autoimmune response must be thoroughly evaluated.
Previous data suggested that MAb 2C7, which bound 13 of 20 separate gonococcal LOS preparations in a solid-phase RIA [10] , might identify a suitable LOS vaccine candidate antigen. We determined an oligosaccharide (OS) epitope of gonococcal LOS identified by MAb 2C7 and characterized the specificity and functional activity of antibody directed against the LOS epitope recognized by MAb 2C7 to assess its potential as a target for a protective gonococcal vaccine candidate.
Materials and Methods
Gonococcal strains and antigens. Transparent, nonpiliated gonococci were grown on solid media supplemented with 1% Isovitalex equivalent [17] for 12-14 h in candle extinction jars at 37°C [18] . LOSs from gonococcal strains WG [19] , 71H [6] , 24-1 [8] , F62 [20] , and WR220 [20] (the latter two, gifts ofH. Schneider, Walter Reed Army Institute of Research, Washington, DC) were prepared from whole organisms using a modification of the hot phenol-water method [21] . Sialylated LOS was prepared from strain 24-1 by overnight growth on solid media flooded (l mLi plate) with 80 j.lg/mL 5' -monophospho-n-acetyl-neuraminic acid (CMP-NANA) before LOS extraction. Gonococcal isolates 1291 and 1291a-e [22] (gifts of M. A. Apicella, University of Iowa, Iowa City) and 15253 (designated DGI 3 in [23] ) [24] were also used in whole cell ELISA. Gonococci were also isolated from patients presenting to the Boston City Hospital (now Boston Medical Center) Sexually Transmitted Diseases Clinic; species were confirmed by routine biochemical testing. Gonococcal OS was prepared from LOS by hydrolysis in 1% acetic acid for 2 h at 100°C followed by centrifugation (200 g, 5 min) [11, 25] . The supernatant was washed three times with CHCl 3 (l :1, vol:vol), and the cloudy phase of the final wash was lyophilized [11, 25] . as fractions were shown to be lipid-free by fatty acid assay [26] . Lipid A (gift of M. A. Apicella) was prepared by acid hydrolysis [27] from N gonorrhoeae 1291.
MAbs and sera. The hybridoma cell line that secretes MAb 2C7 (murine isotype IgG3A [10] ) was prepared by fusion of the murine myeloma cell line Sp2/O-Ag14 to splenocytes [28] taken from a strain A mouse that had been immunized with whole gonococcal outer membranes (prepared from strain WG). MAb 2C7 recognizes gonococcal LOS in solid-phase RIA [10] . Individual cells that secreted antibodies directed against gonococcal LOS were subcloned by limiting dilution. MAb 2C7 was purified from cell culture supernatants over an anti-mouse IgG3-agarose column (Sigma, St. Louis). Purified MAb 2C7 was labeled with biotin (NHS-LC-biotin; Pierce, Rockford, IL; 1.7 nmol ofbiotin/1 nmol of IgG) [29, 30] and used as a probe in the inhibition assays described below. Purified MAb 2C7 was coupled to agarose (AminoLink coupling gel; Pierce) by reductive amination [31] and used as an immunopurificant to remove anti-mouse IgG antibodies in the human sera studied (see below). MAb 3G9 previously has been reported to have binding specificity similar to that of MAb 2C7 [10] . Although initially reported to be of the IgG2a isotype [10] , the 3G9 hybridoma cell line was actually producing two MAbs of different subclass (one IgG3 and one IgG2a) and specificity. We separated the two different 3G9 subclasses by affinity chromatography, using anti-mouse IgG3 (EY Laboratories, San Mateo, CA) and anti-mouse IgG2a (Sigma) coupled to agarose (AminoLink coupling gel; Pierce) as described above, before further study.
Certain MAbs that bind to both gonococcal LOS and human glycosphingolipid antigens were provided by M. A. Apicella (3Fll, 06B4). MAbs 3Fl1 and 06B4 prefer to bind to branched and linear epitopes of the lactoneo series (Gal,BI-4GlcNAc,BI-3-Gal,BI-4Glc), respectively [10, 13, 32] . MAb SH-34 [33] and MAb 103HT30 [34] bind to asialo-GMI (Gal,BI-3NAc,BI-4-Gal,BI-4Glc-cer), but MAb I03HT30 does not bind to gonococci [14] . MAb 2D4 binds to asialo-GM2 (GalNAc,B1-4Gal,BI-4Glc-cer) [35] . In addition, MAbs specific for known as structures commonly expressed on heptose 1 of gonococcal LOS (depicted in figure  IA ) were provided by M. A. Apicella (l-I-M and neisserial-specific 4C4) and W. D. Zollinger (2-1-L8; 9-2-L3,7,9; Walter Reed Army Institute of Research).
Finally, three MAbs that identify an alternative structure, analogous to the erythrocyte p k antigen, expressed on heptose 1 of LOS by some strains of N gonorrhoeae (Galal-3Gal,BI-4Glc) [16] , were also used (figure IB). MAb 3D9 (gift of M. A. Apicella) binds to the erythrocyte p k antigen [14, 43] . Haemophilus infiuenzae-specific MAb 4C4 (gift of E. J. Hansen, University of Texas Southwestern Medical Center, Dallas) was raised against H. influenzae LOS [44, 45] and binds to a digalactoside [46] present on LOS of gonococcal strain 1291b [16] . MAb 17-I-LI (raised against N meningitidis, gift ofW. D. Zollinger) also recognizes the terminal digalactoside structure [36] found on the pk-like structure. Anti-lipid A MAb IC9 [27] was a gift of M. A. Apicella.
Sera were obtained from 6 women with disseminated gonococcal infection and 8 women with gonococcal endometritis and from two sets (n = 23 and n = 11) of normal adult control subjects who had low risk for acquisition of gonococcal or chlamydial disease. The separate sets of control sera were used in two different sets of experiments (see below). Finally, sera obtained from 35 adult male volunteers immunized with a gonococcal vaccine enriched for Por, as part of a 1985 vaccine challenge trial [47] , were assayed for antibody against the 2C7 epitope. The vaccine preparation consisted of~85% Por, but also contained 15% Rmp and small contaminating amounts of LOS (which contained the 2C7 epitope) [47] .
Identification of a conserved in vivo~and in vitro-expressed gonococcal LOS epitope. We used MAb 2C7 to survey for in vivo expression of the 2C7 epitope. The 2C7 epitope was surveyed for in 68 consecutively obtained N gonorrhoeae culture-positive human cervical and male urethral secretions. Polystyrene sticks coated with MAb 2C3 [48] , which is specific for gonococcal H.8 lipoprotein [49] present on all strains, were used to capture antigen. Horseradish peroxidase-conjugated MAb 2C7 was then used to identify the presence of the epitope. Secretions were first diluted 1:6 in assay buffer (0.56% bovine serum albumin [BSA; fraction V, Sigma], 0.34% TritonX-IOO, 0.09 MKH 2P04 , 0.36 MK 2HP04 , 0.11 M NaCl, and 0.06% thimerosal, pH 7.2). Secretions (250 ,uL) were then incubated with the MAb 2C3-coated sticks in 12 X 75 mm glass tubes (1 h, room temperature, intermittent shaking). The sticks were washed with tap water and incubated (1 h, room temperature, intermittent shaking) in a separate tube containing 250 ,uL of horseradish peroxidase-conjugated MAb 2C7 (diluted 1:50 in assay buffer). After another tap water wash, the sticks were incubated in tubes containing 250 ,uL of TMB developer (tetramethyl benzidine in methanol mixed with H 20 2 in citrate phosphate; Sigma). After 10 min of incubation, 100-,uL aliquots were removed from each tube, and absorbance (Ofr) at 630 nm was determined. Positive secretions were defined as those in which the Of) per organism was > I SD above the mean of 6 control (culture-negative) secretions.
Next, we used horseradish peroxidase-conjugated MAb 2C7 to assess binding of this MAb to 101 randomly chosen fresh (secondpassage) isolates of N. gonorrhoeae by whole cell ELISA [50] . In addition, binding of horseradish peroxidase-conjugated MAb 2C7 to strain 24-1 grown in the presence ofCMP-NANA was assessed. To assess for stability of the 2C7 epitope after multiple passage, 3 strains of N gonorrhoeae, shown to express the 2C7 epitope initially, were subpassaged 10 times on solid media supplemented with 1% Isovitalex equivalent [18] and then tested again for the presence of the epitope.
Initial characterization ofthe gonococcal epitope recognized by MAb 2C7. To more rigorously define the gonococcal epitope recognized by MAb 2C7, we subjected gonococci and purified gonococcal LOS to treatment that alters either protein or saccharide epitopes. Whole gonococcal suspensions and purified gonococcal LOS (strain 24-1) were suspended in 1.0 mM EDTA-containing sample buffer [39] either directly or after proteinase K digestion [51] . The samples were subjected to SDS-PAGE, then electroblotted to Immobilon paper (Millipore, Bedford, MA) [52] . Blots of proteinase K-untreated samples were probed either directly or Lacto-N-neotetraose Alternative pk-like structure 3D9, If. influenzae 4C4, I
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A. Figure 1 . General structure of gonococcal LOS (adapted from [36, 37] ). A: Many gonococci express lacto-N-neotetraose tetrasaccharide, identical to human paraglobosides, attached to heptose 1. Some strains append terminal GalNAc residue at site where sialic acid may attach if GalNAc is not present. Binding specificities of monoclonal antibodies (MAbs) l-l-M [38] , 3F11 [10, 13, 32] , L-3,7,9 [36] , 2-l-L8 [39] [40] [41] , and neisserial-specific 4C4 [22] are shown. * In addition to linear ,B-lactosyl structure indicated, MAb 2-l-L8 binds to phosphorylated GlcNAc-Hepl-Hep2 moiety [42] . MAb 2C7 may recognize epitope that includes Gal,BI-4Glc,BI-3-Hep2 structure, exemplified by strain 15253 [24] . B: Gonococci may alternatively express structure, analogous to erythrocyte p k antigen, attached to heptose 1. MAbs 3D9 [14, 43] , Haemophilusinjiuenzae-specific 4C4 [44, 45] , and 17-I-Ll [36] bind this alternative structure.
after incubation with 4 mM NaI0 4 (m-Periodate; Sigma) for 3 h in the dark at room temperature [53] . After washing, all blots were probed with biotinylated MAb 2C7. Periodate treatment oxidizes available vicinal, or adjacent, hydroxyl groups on the OS portion of LOS [54] . To further define the target ofMAb 2C7 recognition, we separated as from lipid A and tested each of these in MAb 2C7-binding assays. as that was prepared by acetic acid hydrolysis, as described above, was derivatized to tyramine to facilitate binding to solid phase [55] . This was followed by ELISA measurement of MAb 2C7 binding to as derivatized to tyramine. LOS and tyraminated as were coated to microtiter plate wells at a concentration of 80 Il-g/mL. Additionally, MAb 2C7 was preincubated (37°C for 1 h) with increasing concentrations of nonderivatized as followed by detection of residual binding to solid-phase homologous LOS (inhibition ELISA [56] ). Binding of MAb 2C7 and anti-lipid A MAb IC9 [27] to neisseriallipid A (prepared by acid hydrolysis) was assessed by immunodot blot assay [57, 58] . Finally, LOSs purified from strains 24-1, WR220, 15253, and 129lc were subjected to 14% SDS-PAGE before Western blotting with MAb 2C7.
Screening for possible cross-reactivity of 2C7 epitope with major and minor human blood group antigens. We used three approaches to assess the possibility that the gonococcal epitope identified by MAb 2C7 might cross-react with human blood group antigens. The first approach was an inhibition ELISA [56] . Strain 24-1 LOS was affixed to microtiter wells, then pre incubated with MAb 2C7. Treated wells were separately incubated with 23 different human sera (from normal blood donors, possessing antibody specificity against erythrocyte types A, B, or 0). The wells were then probed with anti-human IgG or IgM MAb conjugated to alkaline phosphatase (Sigma) to assess the ability of MAb 2C7 to obscure targets on gonococcal LOS that are recognized by human antibodies directed against specific erythrocyte antigens. Values obtained in the inhibition ELISA were compared with values obtained in a direct ELISA [52, 59] (the preincubation step with MAb 2C7 was omitted). The blood donor sera were preabsorbed with anti-mouse IgG agarose (Sigma) to decrease nonspecific binding of the conjugated antibodies. The reverse inhibition assay (incubation of LOS-coated wells with human sera first, then incubation with MAb 2C7 and detection with alkaline phosphataseconjugated anti-mouse IgG antibody [human antibody-absorbed; Sigma]) was also done to assess the ability of human antibodies against erythrocyte antigens to obscure the gonococcal 2C7 epitope.
Second, we used a hemagglutination assay to survey for possible reactivity of MAb 2C7 (in PBS) with types AI, A 2 , B, or a erythrocytes (lmmucor, Norcross, GA). In all hemagglutination assays, erythrocytes (2% in PBS) were mixed with an equal volume of different dilutions of MAb and incubated at 4°C overnight.
Type a erythrocytes sensitized with LOS from strain 24-1 (OLOS erythrocytes) served as a positive control. These agglutination assays were repeated using erythrocytes that had been pretreated with an equal volume of either trypsin (2.5 mg/mL in PBS) or neuraminidase (0.3 U in PBS) for 1 h at 37°C to possibly expose cryptic epitopes. Such enzymatic treatment should expose bloodtype glycose structures obscured by glycoproteins or sialic acid, respectively. This was followed by three washes in PBS to remove enzymes and degradation products [13] . Third, possible cross-reactivity of the 2C7 epitope with human minor blood group and GSL antigens known to cross-react with gonococci [13, 14] was assessed with a competitive ELISA. Direct binding of MAbs 3Fll, 06B4, SH-34, 103HT30, and 2D4 to sialylated and nonsialylated LOS and to whole organisms (strain 24-1, grown in both the presence and absence of CMP-NANA) affixed to solid phase was measured initially. Binding of each MAb was detected using the appropriate anti-murine IgG-or IgM-alkaline phosphatase conjugate (Sigma). Next, those MAbs that bound to either solid-phase LOS or whole organisms were assessed in an inhibition ELISA. In this ELISA, we measured the ability ofbiotinylated MAb 2C7 to compete for binding with GSLdirected MAbs that were positive in the direct ELISA. Nonbiotinylated MAb 2C7 was used as a positive control. Detection was done using avidin alkaline phosphatase (Sigma). In an additional competitive ELISA to assess cross-reactivity against possibly cryptic erythrocyte epitopes, MAbs 3FIl (positive control) and 2C7 were preabsorbed against trypsin-or neuraminidase-treated human erythrocytes (prepared as described above), and then their residual binding to strain 24-1 LOS bound to solid phase was measured.
Screening for possible interactions between 2C7 epitope and MAbs that bind to gonococcal LOS structures attached to heptose 1. As noted above, N. gonorrhoeae elaborate several common OS structures linked to heptose 1 of their LOS (figure 1) (reviewed in [36] ). In addition to MAbs directed against LOS epitopes that cross-react with human GSL antigens, MAbs specifically directed against these common neisserial LOS epitopes are available. Although these MAbs bind to OS structures similar to those bound by the red cell-cross-reactive MAbs, these MAbs recognize distinct epitopes, as discussed below. Using methods described above, we screened these MAbs for any possible interaction with the epitope that is recognized by MAb 2C7. MAb I-I-M binds to a terminal GalNAc residue [38] . Neisseria-specific MAb 4C4 (raised against N meningitidis [22] ) binds to a Gal,BI-4Glc disaccharide structure [16, 61] . MAb 2-1-L8 binds to a similar, but distinct, Gal,BI-4Glc disaccharide expressed on many serum-resistant (SR) gonococci [39] [40] [41] . MAb 9-2-L3,7,9, raised against N meningitidis, binds to an epitope on the Gal,BI-4GlcNAc disaccharide that is similar to, but distinct from, that recognized by MAb 3Fll [36] (figure lA). An alternative LOS structure (Galal-3-Gal,BI-4Glc) is expressed by meningococci of the Ll serotype and some gonococcal isolates on heptose 1 [16, 36] . MAb 17-1-L 1, raised against N. meningitidis, binds the Gala 1-4Gal disaccharide [36] seen by anti-p k MAb 3D9 [14, 43] . H. influenzaespecific MAb 4C4 also binds to such a digalactoside structure [44] [45] [46] (figure IB). Finally, we addressed the possible identity of the epitopes recognized by MAb 3G9 and that recognized by MAb 2C7. Recently, MAbs 3G9 (a mixed population of two MAbs, an IgG3 and an IgG2a) were shown by Yamasaki et al. [24] to bind to most isolates tested from patients with invasive gonococcal disease and to recognize LOS that expresses two lactosyl residues. MAbs 2C7 and 3G9 have been shown to have similar, but not identical, binding to a panel of LOS prepared from 20 gonococcal strains (MAb 2C7 bound 13/20 strains while MAbs 3G9 bound 10120) in solid-phase RIA [10] . After separation of 3G9 into the two subclasses by affinity chromatography (see above), preliminary binding ELISAs indicated that both subclasses bound to whole gonococci. Therefore, each was tested for possible inhibition of MAb 2C7 binding to LOS and for erythrocyte agglutination by several of the methods outlined above.
Demonstration that the 2C7 epitope is a target of bactericidal antibody. Bactericidal assays [17] were done to assess the ability ofMAb 2C7 to effect killing ofthe 3 prototypic gonococcal strains: 24-1 (sialylated or not), WG, and 71H. In separate experiments (data not shown), we have observed that SR strains WG and 71H incorporate only 10% as much CMP-NANA as serum-sensitive (SS) strain 24-1; therefore, bactericidal activity against sialylated variants of strains WG and 71H was not assessed. Murine serum that had been preincubated with glutaraldehyde-fixed homologous gonococci (to remove anti-gonococcal antibodies [62] ) was used as the complement source in these assays.
Opsonophagocytosis assay. The gonococcal opsonization and phagocytosis assay used was a modification of previously described procedures [7, 63] . PMNL were prepared from 30 mL of whole blood from normal adult human volunteers anticoagulated with dipotassium EDTA and centrifuged (500 g, 30 min, room temperature) through Polymorphprep (13.8% sodium metrizoate and 8% dextran 500; Nycomed Pharma, Oslo). Serum and mononuclear cells were carefully removed, and PMNL were transferred to another tube, diluted with an equal volume of 0.45% NaCl, and centrifuged (500 g, 10 min, 4°C) followed by two washes with sterile 0.1 M PBS at 4°C. Contaminating erythrocytes were lysed by exposure to cold sterile water for 30 s before the addition of PBS. The final PMNL pellet was resuspended in PBS (final concentration,2 X 10 7/mL) and kept on ice for use within 30 min. Gonococci were grown in liquid medium [64] , and resuspended in 0.5 mL of 0.1 M NaHC0 3 (pH 9.5) to which 0.5 mL of Lucifer yellow (Sigma) (2 mg/mL in 0.1 MNaHC0 3 , pH 9.5) was added [63] . The mixture was rotated end-over-end for 45 min at room temperature. Organisms were washed thrice and resuspended (5 X 10 8/mL) in HBSS++. Opsonizing antibody (MAb 2C7) was added to the organism suspension (final antibody dilution, 1:100) in a total volume of 250 p,L and incubated for 30 min at 37°C in a rotary shaking water bath. A separate tube of the organism suspension (250 p,L), in buffer alone without opsonizing antibody, was incubated in parallel as a negative control. The opsonized organisms were washed thrice at room temperature in HBSS++, resuspended (5 X 10 8 cells/mL), and chilled on ice for 5 min before use in the phagocytic assay. Aliquots of organisms from the original culture (negative stain control) and of stained organisms (positive stain control) were fixed with Haema-line 2 (Serono-Baker Diagnostics, Allentown, PA) containing 1% paraformaldehyde and kept on ice until analyzed.
Fifty microliters of either opsonized (test) or nonopsonized (control) organism suspension were incubated for 30 min at O°C with 50 f-tL of human PMNL suspension (an optimized ratio of 25 organisms/PMNL, previously determined) in separate reaction tubes to permit adherence of organisms to PMNL without internalization. After this incubation, 1 mL of ice-cold HBSS++ containing 1% BSA was added. PMNL were centrifuged (250 g, 5 min, 4°C) free of unbound organisms. PMNL-adherent organism pellets were resuspended in 100 f-tL of ice-cold 1% BSA-HBSS++, aliquoted into prechilled 12 X 75 mm sterile polystyrene tubes (25 f-tLitube), and kept on ice.
Triplicate aliquots (25 f-tL) of the organism (opsonized or nonopsonized)-PMNL mixtures were then incubated at 37°C in a rotary shaking water bath to allow ingestion. Phagocytosis was stopped by adding 42 f-tL of ice-cold 1% BSA-HBSS++ to one tube every 10 min and transferring that tube into an ice bath. Next, 50 f-tL of ice-cold biotin-labeled MAb 2C3 (0.5 mg/mL) was added to each tube, and the mixture was incubated on ice for 30 min. MAb 2C3 binds to the gonococcal lipoprotein surface antigen H.8 [48] ; thus, it will only bind to gonococci adherent to the surface ofthe PMNL. Cold 1% BSA-HBSS++ (l mL) was added to each tube; this was followed by centrifugation (1500 g, 10 min), resuspension of the pellet in 1% BSA-HBSS++ (l mL), and repeat centrifugation. The final cell pellets were incubated with 1.5 f-tg (6 f-tL) of streptavidinphycoerythrin-Texas red (SAPETR; Life Technologies) on ice for 30 min and washed twice (as above). Finally, the pellets were fixed with 0.5 mL of Haema-line 2 containing 1% paraformaldehyde and stored on ice until analyzed. Lucifer yellow-stained, nonopsonized, and nonphagocytosed organisms were incubated with biotin labeled MAb 2C3 and processed as above to serve as the SAPETR staining control.
Flow cytometric analysis of the fixed PMNL-gonococcal reaction mixtures was done on a single Argon-ion laser FACS (Becton Dickinson, Sunnyvale, CA). Lucifer yellow (green fluorescence) excites at 488 nm and emits at 520 nm (detected in the fluorescence 1 [FL1] channel). Phycoerythrin excites at 488 nm and emits at 575 nm, exciting the adjacent Texas red. Texas red (red fluorescence) then emits at 618 nm (detected mostly in the fluorescence 3 [FL3] channel).
The increase in fluorescence emission in FL 1 and FL3 was expressed as the mean fluorescent channel (the average intensity of fluorescence emitted by 10,000 cells). The intensity of fluorescence directly correlates with the mean fluorescence [65] . Higher mean fluorescence measurements indicated that larger numbers of organisms were adherent to PMNL [66, 67] . As phagocytosis proceeds, fewer gonococci remain exterior to PMNL and are available to bind biotinylated MAb 2C3. Hence, less SAPETR binds (yielding lower emission in FL3), while the total number of Lucifer yellowstained organisms present in the reaction mixtures (both adherent [external] and phagocytosed [internalized]) remains constant (i.e., constant emission in FL 1). A decrease in the net fluorescence, calculated as the mean fluorescence in FL3 (red) minus the mean fluorescence in FL 1 (green), represents internalization of organisms by the PMNL. Aliquots of the reaction mixtures were examined directly by fluorescence microscopy (Carl Zeiss, Thornwood, NY) as a visual control for internalization of organisms.
Human immune response to the gonococcal 2C7 LOS epitope.
Acute and convalescent sera were obtained from 6 women with disseminated gonococcal infection and 8 women with gonococcal endometritis and compared with sera obtained from 11 female controls (blood donors who had low risk for acquiring gonococcal or chlamydial infection). Sera from 35 adult male volunteers immunized with the gonococcal vaccine enriched for Por [47] were also assayed for antibody against the 2C7 epitope. Antibody directed against the 2C7 epitope was determined as the difference between human antibody binding to LOS (bearing the 2C7 epitope) affixed to microtiter plate wells (solid phase) in blocked (preincubation of solid phase-affixed LOS with MAb 2C7) versus unblocked (direct binding) ELlS As [56] . Human sera were absorbed with mouse IgG before use in the assay, as described above. Alkaline phosphatase-conjugated anti-human IgG and IgM antibodies (Sigma) were used for detection. 03 OD U/organism) randomly chosen strains isolated from these patients (serum sensitivity assessed by concomitant bactericidal assay). These data confirm the wide in vivo expression and conservation of this gonococcal LOS epitope, characteristics essential to an effective candidate vaccine antigen.
Results
Survey of in vivo and in vitro expression
MAb 2C7 also bound to 96 of 101 randomly chosen fresh (second-passage) gonococcal isolates by whole cell ELISA. MAb 2C7 bound with equal intensity to strain 24-1 (whole cells and purified LOS) before and after sialylation. Three separate gonococcal isolates that initially expressed the 2C7 LOS epitope maintained stable expression of the epitope through lOin vitro passages, confirming the stability of expression of the epitope.
MAb 2C7 identifies an epitope on gonococcal LOS. To define the binding specificity of MAb 2C7, we first examined MAb 2C7 binding to whole gonococci and to purified LOS (strain 24-1) that had undergone treatment to alter protein or saccharide epitopes. MAb 2C7 bound to several bands on immunoblots of purified LOS and whole celllysates (not shown). Proteinase K treatment did not alter MAb 2C7 binding. MAb 2C7 did not bind to immunoblots of whole cell lysates or LOS that had been incubated with NaI0 4 [54] (not shown). As a control for the efficacy and specificity of both proteinase K treatment and periodation, MAb 3FII (which binds to the terminal Gal,B1-4GlcNAc neisserial LOS epitope [13, 32] LOS prepared from strain 24-1 clearly displayed several bands of molecular size 4.3 kDa and larger, but only the 4.3-kDa band was well-recognized by 2C7 on immunoblot (figure 4). Two additional bands (one 3.6 kDa and one >4.3 kDa) were faintly recognized by MAb 2C7. This result indicates that [39] ; and to single (3,7-3.9 kOa) LOS band expressed by 15253 [24] . MAb 2C7 does not bind to LOS of strain 129lc [16, 22] . strain 24-I expresses several LOS phenotypes but appears not to express the particular 2C7-immunoreactive 3.7-to 3.9-kDa band expressed by strain 15253, which has a LOS characterized by lactosyl (Gal,61-4Glc) substitution of both heptose I and 2 [24] . MAb 2C7 does not recognize LOS of strain 1291c (figure 4), which differs from 15253 LOS in that only heptose I has the lactosyl (Gal,61-4Glc) substitution [16] . Collectively, these data suggest that the 2C7 epitope may involve the lactosyl substitution of heptose 2. MAb 2C7 does not recognize saccharide substitutions off heptos e 1 of gono coccal LOS. Several MAbs that bind to saccharide substitutions off heptose I of gonococcal LOS possess binding specificities, depicted in figure lA, that coincide with the lacto-N-neotetraose tetrasaccharide structure partially identified by MAb 3F II. MAbs I-I-M, neisserial-specific 4C4, and 9-2-L3,7,9 bind to strain 24-1 but do not inhibit binding of MAb 2C7 to whole gonococci or purified LOS in ELISA. MAb 2-I-L8 binds to the LOS of gonococcal strain WR220 but does not inhibit binding of MAb 2C7 to WR220 LOS in ELISA. In addition, MAb 2C7 does not bind to the LOS of gonococcal strain 1291 or its pyocin mutants, which assemble sequentially increasing numbers ofhexoses attached to heptose I [16] . These results indicate that the epitope identified by MAb 2C7 does not reside on the known lacto-N-neotetraose substitutions off heptose I of gonococcal LOS.
An alternative structure substituted off heptose I of gonococcal LOS is Gala 1-4Gal (shown in figure I B and exemplified by gonococcal pyocin mutant strain 1291b [16] ) . MAb 3D9 (anti-P', which bound to 51% of N. gonorrhoeae strains previously surveyed [14] ) and H. ilijluenzae-specific MAb 4C4 (bound to 24% of gonococcal isol ates previously surveyed [46] ) both bind to this Gal-Gal ep itope. MAb 17-I -Ll binds Gala 1-4Gal that is expressed by meningococci ofthe Ll serotype and some gonococci [16, 36] . These MAbs did not bind to whole gonococci or purified LOS (strains 24-1 and 15253) that otherwise expressed the 2C7 epitope. Gonococcal isolates known to express this alternative digalactoside structure (strains 1291b, F62, and 4505 [14 , 36] , unpublished data) did not bind MAb 2C7. These data indicate that MAb 2C7 does not recognize this digalactoside structure.
Meningococcal LOS is also characterized by the elaboration ofa variable number of hexose residues attached to heptose I of the core region [54, 68] . These include the lacto-N-neotetraose structure, also expressed in N. gonorrhoeae, that undergoes phase-variable expression regulated by an identical slippedstrand mispairing mechanism [69] . The L3, 7,9 epitope resides in the lacto-N-neotetraose region (figure I) [68, 69] . The L8, L I0, and L II epitopes reside in the OS chain off heptose I , but phosphorylation of the diheptose core region is critical for full expression [24, 54] Because considerable evidence exists supporting cross-reactivity between gonococcal LOS epitopes and numerous human GSL antigens, we assessed the possibility that the LOS epitope identified by MAb 2C7 might cross-react as well. Initial screening for similarity to major blood group antigens was done by inhibition ELISA. Twenty-three sera obtained from human blood donors (6 type A -shown to have antibody directed against blood group B antigen, 9 type a-antibody against both A and B, and 8 type B-antibody against A) were surveyed. These sera contained a mean (± SE) IgG level of 2.46 ± 0.51 I-lg/mL and IgM of 1.52 ± 0.02 I-lg/mL directed against strain 24-1 LOS. Binding by these sera to strain 24-1 LOS affixed to microtiter plate wells was not inhibited by MAb 2C7. In the reverse assay, no inhibition of MAb 2C7 binding to strain 24-1 LOS by these sera was detected.
MAb 2C7 (diluted in PBS) did not agglutinate type At, A z , B, or 0 erythrocytes but did agglutinate the positive control OLOS erythrocytes. The control human sera agglutinated type At, A z , B, or 0 erythrocytes as expected on the basis of donors' blood types. All three types of erythrocytes were agglutinated by MAb 3F 11, which identifies a branching I antigen-like human erythrocyte developmental structure, as has been demonstrated by others [13] . Addition of anti-murine IgM extended the agglutination end point of MAb 3Fll (an IgM MAb) by 16-fold (from 1.3 X 10-3 down to 8 X 10-5 I-lg/mL), but antimurine IgG did not uncover any binding ofMAb 2C7 (an IgG3 MAb) to human erythrocytes. When guinea pig complement was added to the system and hemolysis was used as the indicator, the end points were not extended. Thus, the epitope identified by MAb 2C7 is not similar to the major glycosphingolipid precursor of human blood group antigens (recognized by crossreactive MAb 3Fl1 [13] ).
MAb 3Fll-mediated agglutination of erythrocytes can be increased by both trypsin and neuraminidase treatment to unmask cryptic epitopes obscured by glycoproteins or sialic acids, respectively [13] . Our data reproduced those results, but neither trypsin nor neuraminidase treatment caused MAb 2C7 to agglutinate unsensitized erythrocytes. Similarly, ELISA data indicate that preabsorption of MAb 3Fll with either trypsin-or neuraminidase-treated erythrocytes (compared to preabsorption with untreated erythrocytes) reduced residual binding to solidphase 24-1 LOS by~50% and 95%, respectively, while residual binding of MAb 2C7 to LOS was unchanged by absorption with enzyme-treated erythrocytes.
MAb 2C7 does not bind cross-reactive human GSL antigens. MAbs that recognize human GSL antigens previously shown to cross-react with gonococcal LOS epitopes [13, 14] were screened for binding to whole gonococci and purified LOS that express the 2C7 LOS epitope (strain 24-1). As expected, MAbs 3Fll (which prefers branching over linear lactosamine structures) and 06B4 (which prefers linear lactosamine) bound both to purified LOS and whole gonococci (strain 24-1), as did MAb 2D4 (anti-asialo-GM2, which bound to 54% of N gonorrhoeae strains previously surveyed [14] ). However, MAbs 3Fll, 06B4, and 2D4 did not inhibit binding of MAb 2C7 to either purified LOS or whole gonococci (strain 24-1). This indicated absence of cross-reactivity between the 2C7 LOS epitope and the lactoneo series or asialo-GM2 human GSL antigens. MAb SH-34 (anti-asialo-GMl, which exhibits variable binding to gonococci [14] ) bound to whole gonococci but not purified LOS (strain 24-1); MAb SH-34 did not inhibit binding ofMAb 27C. MAb 103HT30, a separate MAb that also binds asialo-GMI antigen [14] , did not bind to 2C7-containing LOS. Overall, use of whole gonococci (strain 24-1) or LOS purified from strain 24-1 grown in the presence of CMP-NANA did not alter the results, although sialylation did produce the expected reduction of binding by MAbs 3Fll and 06B4 [13] . Taken together, these data indicate that the epitope identified by MAb 2C7 lacks antigenic similarity to previously identified crossreactive human GSL antigens and thus may not be expected to evoke an autoimmune response.
MAb 2C7 identifies a bactericidal target on both SS and SR gonococci. MAb 2C7 has bactericidal activity against SS (strain 24-1), sialylated SS (phenotypically SR) strain 24-1, and SR (strain WG) gonococci that express the 2C7 LOS epitope. In this experiment, a murine complement source that had been preabsorbed against the homologous strain [62] was used. As shown in figure 5 , 45 I-lg of MAb 2C7 in the reaction mixture (the highest concentration used) mediated 100% killing of the SS strain 24-1, 36% killing of the sialylated (phenotypically SR) strain 24-1, and 29% killing of SR strain WG. MAb 2C7 was unable to kill, at any concentration used, SR gonococci (strain 71H) that lacked the 2C7 LOS epitope, confirming the specificity of the bactericidal activity. Killing of phenotypically SR gonococci mediated by MAb 2C7 did not achieve the 50% level in this experiment, but a dose-response was seen. Since murine IgG3A does not fix murine complement as efficiently as other subclasses [70] , this may have influenced the degree of killing observed with MAb 2C7. Nevertheless, this result suggests that immunization designed to elicit specific anti-2C7 antibody could mediate bactericidal activity against both SS and SR gonococci. Immunization of mice with an anti-idiotope MAb that mimics the 2C7 epitope elicited an antibody response that possessed at least I loglo greater killing activity against both SS and SR gonococci than that elicited by immunization with LOS [71] .
MAb 2C7 mediates opsonophagocytosis of both SS and SR gonococci. Control experiments were done to establish baseline mean fluorescence of organisms after staining with Lucifer yellow and counterstaining the biotinylated MAb 2C3-SA-PETR complex and to demonstrate that SAPETR counterstaining did not quench the green fluorescence due to Lucifer nn 1996; 174 (December) Figure 5 . Bactericidal activity of monoclonal antibody (MAb) 2C7. MAb 2C7 is able to effect murine complement-mediated killing of serum-sensitive (24-1) and -resistant (WG) gonococcal strains expressing 2C7 epitope. Although sialylation of strain 24-1 does not abolishrecognition of 2C7 epitope, it decreased amountof killing observed. No killing of strain that does not express 2C7 epitope (71 H) was observed. yellow . In addition, the mean fluorescence in FL 1 (green) remained constant in the individual reaction tubes during the incubation period, thus permitting accurate quantitation of the number of organisms present in the reaction mixtures. Corroboration of the flow cytometric data was obtained by direct fluorescent microscopic examination of samples obtained concurrently from the PMNL-organism reaction tubes . At time zero, all organisms were observed to be exterior to the PMNL and yellow in color. After 30 min at 37°C, most of the organisms were observed to be inside the PMNL and green in color (indicating internalization). As a measure of adherence, the number of organisms bound to PMNL (at DoC) before the ingestion step (at 37°C) were compared (O-min time points in figure 6 ). Comparing unopsonized organisms, both SS strain 24-1 and SR strain WG gonococci exhibited greater adherence to PMNL than did SR strain 71H. Preincubation of organisms with the primary antibody, MAb 2C7, increased adherence to PMNL of strain 24-1 by 40% and of SR strain WG by 84%. No change in adherence of SR strain 71H (does not express the 2C7 LOS epitope) was mediated by MAb 2C7.
Ingestion (phagocytosis) of organisms was measured during a 3D-min incubation at 37°C (figure 6). Between 10% and 22% of all 3 nonopsonized gonococcal strains were ingested by PMNL by 30 min . Opsonization with MAb 2C7 alone mediated almost complete ingestion by human PMNL (indicated by a decrease in net fluorescence to near 0 at 30 min) of the 2 gonococcal strains expressing the 2C7 LOS epitope (SS strain 24-1 and SR strain WG) but did not mediate ingestion above control levels of the strain that did not express the 2C7 epitope (SR strain 71H).
Characterization ofmagnitude and functional activity ofhuman immune response to 2C7 LOS epitope as a result ofgonococcal infection or vaccination. The levels of IgG and IgM antibody directed against the 2C7 LOS epitope were measured in acute and convalescent sera obtained from 6 women with disseminated gonococcal infection and 8 women with gonococcal endometritis (confirmed by culture and endometrial histopathology) whose infecting organisms were shown to maintain the 2C7 LOS epitope. Both disseminated gonococcal infection and endometritis patients developed significant anti -2C7 LOS epitope antibody responses (calculated as described in Materials and Methods and shown in figure 7 as the mean ± SE) . Anti -2C7 LOS epitope antibody levels in 11 female blood donor controls were significantly lower (mean IgM = 0.011 ± 0.003 tlg/mL; mean IgG = 0.031 ± 0.021 tlg/mL; P < .0 1 by Wilcoxon rank sum test) than those evoked by gonococcal infection. In addition, convalescent sera obtained from 2 patients with disseminated gonococcal infection (1 of whom had 2 tlg/mL anti-LOS IgG against strain 24-1 LOS [56] ) who were infected with strains that did not exhibit the 2C7 LOS epitope showed no increase in anti -2C7 LOS epitope antibody, indicating specificity of the measured response. Twenty-eight of 35 persons vaccinated with the Por-enriched vaccine [47] developed a > 2-fold rise in antibody levels against LOS (mean, 4.3-fold increase; figure 8 ). Twenty of these 28 vaccinees demonstrated a rise in antibody (~O.l tlg/mL) directed against the 2C7 epitope (mean, 44.5-fold increase). Eleven of these 20 developed an excess level of antibody against the 2C7 epitope compared with their overall response to LOS.
Discussion
Natural infection with N. gonorrhoeae elicits a humoral immune response against LOS that mediates complement activa- Despite these positive attributes, factors such as the variability of gonococcal LOS as demonstrated in vitro [10] [11] [12] likely hinder the development of a broadly protective immune response. The current studies characterize a conserved, widely in vivo-expressed epitope present on gonococcal LOS that potentially may serve as target for a preventive vaccine candidate. We demonstrated recognition of the 2C7 LOS epitope in 94% of culture-positive genital secretions using the MAb 2C3 stick capture technique described. This technique permits a more accurate assessment of in vivo epitope expression, because even one in vitro passage may allow for antigenic variation [37] . The finding that MAb 2C7 recognizes 95% of fresh (secondpassage) isolates indicates that the 2C7 LOS epitope is well conserved in vivo despite the considerable heterogeneity exhibited by most gonococcal LOS [10] [11] [12] . Much of the variability observed appears to derive from shifts in the number of guanosine residues in poly-guanine tracts of the genes encoding the biosynthetic enzymes responsible for assembling the saccharide structures attached to heptose 1 ofgonococcal LOS [36, 72, 73] . Importantly, expression of the epitope (measured as binding of MAb 2C7 per organism) was no different between gonococci exhibiting the SS or SR phenotypes [5, [74] [75] [76] . In addition, expression of the epitope remained stable after multiple in vitro passages of our prototypic laboratory strains and was not abrogated by in vitro sialylation. These data establish that the 2C7 LOS epitope is both conserved and widely expressed in vivo, both of which are essential characteristics in terms of vaccine development.
Further definition of the molecular nature of this gonococcal LOS epitope was provided by examination of MAb 2C7 bind- Figure 7 . lmmunogenicity of 2C7 epitope in patients with gonococcal infection. Binding of acute and convalescent sera from patients with disseminated gonococcal infection (DGI; n = 6) and gonococcal endometritis (n = 8) to solid-phase strain 24-1 LOS was assessed in inhibitionELISA. Specific antibody directed against 2C7 epitope was determined by subtracting Of) readings obtained after blocking solidphase LOS with monoclonal antibody 2C7 from unblocked readings. Anti-human IgM-and IgG-alkaline phosphatase conjugates were used. Values are mean ± SE of 2 experiments.
ing to whole gonococci and purified LOS after treatment to alter protein or saccharide epitopes. Proteinase K treatment did not alter binding, indicating that the 2C7 epitope does not contain protein. Periodation, which oxidizes vicinal hydroxyl groups on the OS portion of LOS [54] , abolished binding of MAb 2C7, suggesting that the epitope is an OS . Next, using 2 prototypic SS and SR strains that express the 2C7 LOS epitope, MAb 2C7 binding to whole organisms, purified LOS , and tyraminated OS was equivalent (figure 2). Additionally, preincubation with nontyraminated OS strongly inhibited MAb 2C7 binding to homologous LOS (figure 3). MAb 2C7 did not bind to purified neisserial lipid A. This suggested that the epitope is not in the lipid A portion of the LOS molecule and is located in the OS portion of gonococcal LOS . Furthermore, the data suggest that the epitope does not encompass both core 2-keto-3-deoxyoctonate (KDO) residues because acid hydrolysis of neisserial LOS (which did not alter MAb 2C7 binding) yields OS containing two heptose residues and only one KDO residue [15, 16] , while intact LOS contains two KDO residues [77] . These results do not exclude the possibility that MAb 2C7 binds to other functional groups in the OS moiety such as phosphate or acetate groups presumably attached to the hydroxyl groups of the di-heptose residues or that the binding specificity could be conformational. Finally, MAb 2C7 binds to strain 15253 LOS, which possesses lactosyl (Gal,B1-4Glc) substitutions of both heptose residues [24] , but not to strain 1291c LOS (figure 4), which differs from 15253 by the lack of this lactosyl substitution on heptose 2 [16] . These data suggest that the 2C7 epitope may involve the lactosyl (Gal,BI-4Glc) substitution of heptose 2.
IgG (ug/ml) 2 Figure 8 . Anti-LOS and 2C7 epitope antibody measurements in 28 subjects before (pre) and after (post) immunization with gonococcal porin-enriched vaccine preparation [47) . Direct binding to solidphase strain 24-1 LOS was initially assessed (anti-LOS IgG). Specific antibody directed against 2C7 epitope (anti-2C7 IgG) was determined by subtracting Ol) readings obtained after blocking solid-phase LOS with monoclonal antibody 2C7 from unblocked readings. Anti-human IgG-alkaline phosphatase conjugate was used. Values are means of 2 experiments. Levels of total anti-LOS and specificanti-2C7 epitope IgG increased 4.3-and 44.S-fold, respectively, after immunization.
Given the substantial evidence that gonococci possess epitopes that mimic those found on human erythrocyte and genital epithelial GSLs [13, 14] , the possibility that the 2C7 epitope is such a cross-reactive site was evaluated. Cross-reactive MAbs that recognize paragloboside (MAbs 06B4 [prefers linear lactosamine] and 3FII [prefers branching lactosamine]), globotriose (MAbs 3D9 and 4C4), asialo-GMI (MAb SH-34), and asialo-GM2 (MAb 2D4) structures all bind to epitopes created by OS chain elongations on heptose 1 of gonococcal LOS [13, 14, 24] . MAbs 2C7 and 06B4 bind to different molecular weight LOS components of gonococcal strain WR220 and do not compete with each other for binding to either outer membrane complexes or purified LOS [10] . Although MAb 3Fll agglutinates adult human erythrocytes of all three major ABO types [13] , MAb 2C7 did not agglutinate any erythrocyte type except the positive control OLOS erythrocytes . Addition of a secondary anti-murine antibody (to facilitate cross-linking of MAb 2C7 bound to erythrocytes at low density) did not uncover any binding, nor did the addition of complement to the system (to enhance sensitivity), although secondary anti-murine antibody increased MAb 3FII detection end points by two 4-fold dilutions.
Our Recently, MAb 3G9 was shown to recognize LOS that possesses a lactosyl (Gal,8l-4Glc) residue attached to heptose 2 on invasive gonococcal strains [24] . MAb 3G9 has been reported to bind to two of the three major LOS components of gonococcal strain WR220 [10] . Our data indicate that on immunoblot, MAb 2C7 binds strongly to a 4.3-kDa band and weakly to two bands (one of 3.6 kDa) of strain 24-1 LOS [11] and to the 3.6-and 4.3-kDa bands of WR220 LOS (figure 4). MAbs 3G9 and 2C7 showed similar binding patterns to LOS from 20 gonococcal strains by solid-phase RIA analysis, and neither competed with MAb 06B4 for binding to strain WR220 [10] . However, MAb 3G9 was reported to only minimally displace MAb 2C7 from strain WR220 LOS [78] . We found that the hybridoma cells producing MAb 3G9 (as used in other studies [10, 24, 78, 79] ) actually yielded two different subclasses of MAbs of differing specificity. Although both 3G9 subclasses bound to gonococci, only MAb 3G9 IgG3 (not MAb 3G9 IgG2a) was able to inhibit binding of MAb 2C7 to gonococci. MAb 3G9 IgG2a agglutinated erythrocytes, while the MAb 3G9 IgG3 did not, even after trypsin or neuraminidase pretreatment. The data indicate that MAbs 2C7 and 3G9 IgG3 both bind to a similar epitope on gonococcal LOS that is separate from the erythrocytic cross-reactive epitope bound by MAb 3G9 IgG2a. Recent structural studies indicate that MAb 3G9 IgG2a (designated as 3G9-A in [79] ) binds to a blood group A glycosphingolipid epitope consisting of the trisaccharide, GaINAcal-3(fucal-2)Gal [79] . MAb 2C7 binding is not inhibited by MAbs previously demonstrated to bind the known lacto-N-neotetraose epitopes or the alternative digalactoside structure contained on the OS chain of heptose 1 of gonococcal or meningococcal LOS. Collectively, these data and those shown in figure 4 suggest that the 2C7 epitope is likely to involve the Gal,81-4Glc substitution of heptose 2 of gonococcal LOS (figure 1) that is also bound by MAb 3G9 IgG3 [24] . Nevertheless, comprehensive molecular definition of the 2C7 epitope awaits more detailed biochemical analysis.
In addition to wide exposure in vivo, an antigen that is chosen as a target for a potentially preventive vaccine should elicit an immune response that is functionally active against the organism. We demonstrate that MAb 2C7, with homologous strain-absorbed murine complement, has specific in vitro killing activity against prototypical SS and SR gonococci that express the epitope. Sialylation of the SS strain decreased, but did not abolish, the level of killing. Although binding of MAb 2C7 was equivalent to sialylated and nonsialylated variants, differential degrees of killing implicate a possible effect of sialic acid on complement activation, as shown in other systems [80] [81] [82] . Sialylation of organisms did not decrease binding of MAb 2C7; therefore, steric hindrance of binding is unlikely to account for the majority of the effect seen. MAb 2C7 was also able, in the flow cytometric assay described, to mediate complete phagocytosis of gonococci expressing the 2C7 epitope by human PMNL in the absence of complement. MAb 2C7 is of the murine IgG3 isotype, which has been shown to bind with high affinity to the FcyRI receptor (and with lower affinity to the FcyRII and FcyRIII receptors) expressed on human PMNL; FcyRI and FcyRII are in tum capable of mediating phagocytosis of MAb-coated erythrocytes [83] . These data establish the 2C7 LOS epitope as a bactericidal and opsonophagocytic target.
Evidence of the in vivo immunogenicity of the 2C7 LOS epitope in humans was provided by survey of two types of subjects: subjects recovering from natural infection and subjects immunized with a prototypic vaccine. Women infected with gonococci expressing the 2C7 LOS epitope developed significant rises in both IgM and IgG antibody titers against the epitope, with those recovering from disseminated infection developing higher titers than those with endometritis ( figure  7) . A specific IgG antibody response to the 2C7 LOS epitope was elicited by vaccination with a Por-enriched vaccine contaminated with small amounts of LOS [47] . Eleven of 28 vaccinees developed an excess of IgG antibody against the 2C7 epitope compared to their overall response to LOS (figure 8). This vaccine did not prevent experimental gonococcal infection, a result that can likely be attributed to factors such as the development of responses that subvert the effects of bactericidal antibody (e.g., anti-Rmp blocking antibody) [47] . The levels of specific anti-2C7 epitope IgG antibody elicited in this trial were low « 1 j.lg/mL) and therefore unlikely to overcome these subversive effects. Nonetheless, these data support the immunogenicity of the 2C7 LOS epitope. Immunization of animals with a monoclonal anti-idiotope antibody that mimics the 2C7 LOS epitope evoked a 2C7 epitope-specific, functional antibody response [71] . Serum IgG antibody has been postulated to be sufficient to confer protection against infectious diseases and may do so by local inactivation of the inoculum [84] . Significantly elevated levels of anti-gpl60 IgG have been found in vaginal secretions ofwomen infected with human immunodeficiency virus [85] . Parenteral vaccination with tetanus toxoid elicited serum and vaginal IgG antibody responses with identical specific activity and avidity [86] . Therefore, an IgG antibody response generated by parenteral immunization against the 2C7 epitope could lead to a protective response at the local level.
In summary, MAb 2C7 recognizes a gonococcal LOS epitope that is conserved and widely expressed in vivo, does not cross-react with human GSL antigens, and is a bactericidal epitope that evokes a significant immune response after natural infection and vaccination. These qualities indicate that the 2C7 gonococcal LOS epitope is worthy of more extensive investigation as the target of a potential vaccine candidate.
